Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Beat The Street With SI Traders -- Ignore unavailable to you. Want to Upgrade?

To: teevee who wrote (214051)	9/21/2021 2:12:59 PM
From: russet	5 Recommendations Recommended By Clark Kent Frankly Speaking johnlw kidl Rocket Red Read Replies (1) \| Respond to of 233807

I have watched too many people I know die of Covid, at and above my age. The decision was a choice between two evils,...the chance of dying or being maimed by Covid and associated infections and conditions, and the chance of dying or being maimed by the trillions of spike proteins the current vaccines produce. Mixed into the decision was the fascist intent of the government and many businesses to deny me the ability to travel and access to where I want to go, if I was not vaccinated. We are witnessing an inquisition against unvaccinated people in many countries. Climate change crap is also producing inquisitions against anyone who does not believe and accept our political masters decries. We have not progressed very far intellectually from our ancestors of hundreds of years ago and the religious inquisitions of the past. We are all slaves to the whims of the political and business elite, and they are selfish and stupid, but if you speak out against them they will martyr you. I trust (hope) my immune system and body will destroy the spike protein and clear it from my system. It is however clear to me that it is impossible for humans to stop the transmission of Covid and its variants from infecting us, and that this virus was designed to resist mutation to less virulent forms, like natural virus. Eventually we will all get infected. I don't want to gamble that I will survive the infection without health consequences. I also don't want to fight a mob of ignorant, uneducated morons who believe whatever they are told without looking at the evidence. Good luck to us all.

To: teevee who wrote (214051)	9/23/2021 2:55:41 PM
From: russet	Respond to of 233807

This company is studying what causes the life-threatening side effects such as abnormal blood clotting and nyocarditis in both the virus induced disease and the vaccine induced side effects (all related to the spike protein). They are testing a vaccine that would modify the spike protein so it may stop these life threatening side effects. High blood pressure, abnormal blood clotting, headaches, tiredness, inability to concentrate and many other side effects of the vaccine could be explained by this mechanism. Biovaxys begins study re vaccine side effects 2021-09-23 07:23 ET - News Release Mr. James Passin reports BIOVAXYS PREPARES FOR GROUNDBREAKING STUDY ON REDUCED ACE2 BINDING CAPABILITIES OF HAPTEN-MODIFIED SARS-COV-2 PROTEINS Biovaxys Technology Corp. has initiated what could be a scientifically groundbreaking study on the reduced ACE2 binding capabilities of the hapten-modified spike protein that is the foundation of BVX-0320, the company's SARS-CoV-2 vaccine. Many SARS-CoV-2-infected patients develop pneumonia that may lead to acute respiratory distress, with some patients developing cardiac symptoms and cardiovascular injury. In its peer-reviewed research paper, "SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19," published in the Journal of Hematological Oncology, S. Zhang et al. (1) conclude that the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein binds to the ACE2 receptor and that this binding of SARS-CoV-2 to ACE2 prevents the enzyme from converting angiotensin II, potentiating pulmonary and cardiovascular issues. Currently available vaccines, whether comprising recombinant full-length or partial spike protein can result in rare, but life-threatening side effects, such as abnormal blood clotting or myocarditis. These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4. The Biovaxys vaccine for COVID-19, BVX-0320, comprises a portion of the spike protein that is modified by the hapten, dinitrophenyl (DNP). Biovaxys believes that the haptenized spike protein has much-diminished ability to bind to ACE2, which would result in much-diminished vaccine toxicity. David Berd, MD, chief medical officer of Biovaxys, explained that "Biovaxys will compare the binding of haptenized spike protein with the non-haptenized. The results could provide evidence that our vaccine has lowered potential for some of the observed serious vaccine side effects." James Passin, Biovaxys chief executive officer, stated, "Haptenization, as a method to inhibit the ACE2-binding ability of the spike protein, while increasing its immunogenicity, may prove to play a critical role in global COVID-19 vaccine development and deployment strategies, as public health authorities consider options for repeated seasonal vaccine boosters in the context of reported, albeit rare, adverse effects and apparent waning immunity." This week Biovaxys entered into an agreement with Millipore-Sigma, a global contract development and manufacturing research organization (CDMO), to manufacture a supply of GLP-grade BVX-0320, the company's SARS-CoV-2 vaccine candidate for the study. Millipore produced similar yields of BVX-0320 last summer for the company's animal immune response studies, but will now be incorporating in manufacturing the recently produced purified recombinant s-protein produced by Biovaxys bioproduction partner, WuXi Biologics. Millipore is a subsidiary of Merck KGaA, one of the largest pharmaceutical companies in the world, with a market capitalization of $102-billion (U.S.). Biovaxys is currently finalizing arrangements with a major U.S. academic research institution that will be collaborating with the company on the study. For greater certainty, Biovaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time. (1) J Hematol Oncol 2020 Sep 4;13(1):120. About Biovaxys Technology Corp. Based in Vancouver, Biovaxys Technology is a British Columbia-registered, clinical-stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for stage III/stage IV ovarian cancer. Also in development is CoviDTH, a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. Biovaxys has two issued U.S. patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (COVID-19) vaccine and diagnostic technologies.